The Limited Times

Now you can see non-English news...

Vaccines: AstraZeneca spared by justice

2021-06-22T16:44:54.493Z


The tone was however to the satisfaction of the European side, stressing that the decision recognizes a "serious fault" of the laboratory.


Contrary to appearances, the scales are tipping for AstraZeneca.

A Belgian court of first instance orders the Swedish-British company to deliver 50 million doses to the European Union before October, on pain of a fine of 10 euros for each dose that does not arrive within the time limit.

It is in fact a setback for the European Commission, which claimed 90 million by the end of June, and much higher penalties.

Read also:

Vaccine deliveries: EU demands heavy compensation from AstraZeneca

The figure appears all the more ridiculous since, since the launch of the procedure in March, AZ has already delivered 40 million doses. The firm must therefore provide just over 10 million doses by the end of the summer, which it says it can do without problem by the end of June. The European Union, if it does not appeal, will therefore not get more vaccines than it probably would have received over the summer. The court also rejects the EU's request for a detailed and binding timetable to reach the 300 million doses provided for in the contract.

The tone was however to the satisfaction on the European side, stressing that the decision recognizes a "

serious fault

" of the laboratory which would have "

deliberately

" violated its contractual obligations vis-à-vis the EU.

"

The court considers that the refusal to use the Oxford Biomedica plant is a violation

" of the contract, welcome the lawyers of the European executive.

They believe that the company will now have to use this vaccine production site for Europeans, and not just for other customers.

Read also:

Vaccination: why it is recommended to receive the two doses in the same place

An interpretation rejected by the representatives of AstraZeneca. "

The only obligation

" concerns the delivery of 50 million doses, and no "

exclusivity or priority right

" is given to the Commission, analyzes the company. Overall, the laboratory disputes the value given by the Union to this decision for interim relief. The real decision will come later, in the substantive proceedings.

Source: lefigaro

All news articles on 2021-06-22

You may like

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.